EP1087661A4 - Antagonistes des recepteurs d'il-8 - Google Patents

Antagonistes des recepteurs d'il-8

Info

Publication number
EP1087661A4
EP1087661A4 EP99928764A EP99928764A EP1087661A4 EP 1087661 A4 EP1087661 A4 EP 1087661A4 EP 99928764 A EP99928764 A EP 99928764A EP 99928764 A EP99928764 A EP 99928764A EP 1087661 A4 EP1087661 A4 EP 1087661A4
Authority
EP
European Patent Office
Prior art keywords
receptor antagonists
antagonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99928764A
Other languages
German (de)
English (en)
Other versions
EP1087661A1 (fr
Inventor
Katherine L Widdowson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1087661A1 publication Critical patent/EP1087661A1/fr
Publication of EP1087661A4 publication Critical patent/EP1087661A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
EP99928764A 1998-06-17 1999-06-17 Antagonistes des recepteurs d'il-8 Withdrawn EP1087661A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8963398P 1998-06-17 1998-06-17
US89633P 1998-06-17
PCT/US1999/013739 WO1999065310A1 (fr) 1998-06-17 1999-06-17 Antagonistes des recepteurs d'il-8

Publications (2)

Publication Number Publication Date
EP1087661A1 EP1087661A1 (fr) 2001-04-04
EP1087661A4 true EP1087661A4 (fr) 2003-04-16

Family

ID=22218727

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99928764A Withdrawn EP1087661A4 (fr) 1998-06-17 1999-06-17 Antagonistes des recepteurs d'il-8

Country Status (4)

Country Link
EP (1) EP1087661A4 (fr)
JP (1) JP2002518300A (fr)
CA (1) CA2335292A1 (fr)
WO (1) WO1999065310A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997001354A1 (fr) * 1995-06-27 1997-01-16 Genentech, Inc. Antagonistes d'il-8 utilises pour le traitement des troubles inflammatoires et de l'asthme
WO1997049680A1 (fr) * 1996-06-27 1997-12-31 Smithkline Beecham Corporation Antagonistes des recepteurs d'il-8
WO1998032439A1 (fr) * 1997-01-23 1998-07-30 Smithkline Beecham Corporation Antagonistes du recepteur de l'il-8

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0809492A4 (fr) * 1995-02-17 2007-01-24 Smithkline Beecham Corp Antagonistes des recepteurs d'il-8

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997001354A1 (fr) * 1995-06-27 1997-01-16 Genentech, Inc. Antagonistes d'il-8 utilises pour le traitement des troubles inflammatoires et de l'asthme
WO1997049680A1 (fr) * 1996-06-27 1997-12-31 Smithkline Beecham Corporation Antagonistes des recepteurs d'il-8
WO1998032439A1 (fr) * 1997-01-23 1998-07-30 Smithkline Beecham Corporation Antagonistes du recepteur de l'il-8

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9965310A1 *

Also Published As

Publication number Publication date
JP2002518300A (ja) 2002-06-25
CA2335292A1 (fr) 1999-12-23
EP1087661A1 (fr) 2001-04-04
WO1999065310A1 (fr) 1999-12-23

Similar Documents

Publication Publication Date Title
ZA988100B (en) IL-8 receptor antagonists
IL131004A0 (en) Il-8 receptor antagonists
EP1000017A4 (fr) Antagonistes du recepteur il-8
IL145761A0 (en) Il-8 receptor antagonists
IL131005A0 (en) Il-8 receptor antagonists
IL145762A0 (en) Il-8 receptor antagonists
IL134854A0 (en) Il-8 receptor antagonists
PL351946A1 (en) Il-8 receptor antagonists
EP0971908A4 (fr) Antagoniste de recepteurs d'il-8
IL146053A0 (en) Il-8 receptor antagonists
EP1039903A4 (fr) Antagonistes des recepteurs de l'interleukine-8
EP1047424A4 (fr) Antagonistes des recepteurs il-8
HK1044717A1 (zh) Il-8受體拮抗劑
IL140983A0 (en) Il-8 receptor antagonists
HK1044475A1 (zh) Il-8受體拮抗劑
ZA985813B (en) IL-8 receptor antagonists
ZA985975B (en) IL-8 receptor antagonists
EP1121360A4 (fr) Antagonistes du recepteur de l'interleukine-8 (il-8)
EP1087661A4 (fr) Antagonistes des recepteurs d'il-8
HUP0202004A2 (en) Il-8 receptor antagonists
HUP0202019A2 (en) Il-8 receptor antagonists
ZA98519B (en) Il-8 receptor antagonists
EP1237548A4 (fr) Antagonistes du recepteur de il-8

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001228

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI NL

A4 Supplementary search report drawn up and despatched

Effective date: 20030303

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030528